The infection caused by COVID19 worldwide makes it necessary to monitor drugs administered for the treatment of patients hospitalized with SARS-CoV-2. In order to know more about the efficacy and safety of the treatments used, researchers from the Cantabrian health service have developed an observational study, in the form of an ambispective registry, in which clinical data from patients treated with the different drugs currently recommended by the Spanish Agency of Medicines and Health Products (SAMHP) and the Ministry of Health, or others that may arise, are collected and analyzed. Although the conduct of clinical trials is a priority at this time, we cannot lose the clinical experience that is currently being generated, which may allow us to improve the therapeutic strategies for future patients.
Drug: Patients with the treatment agains COVID19
Data will be collected from patients who receive any of the treatments included in the "Technical Document. Manejo clínico del COVID-19: tratamiento médico" of the Ministry of Health, and "Tratamientos disponibles para el manejo de la infección respiratoria por SARS-CoV-2" of the AEMPS, either as antivirals or as treatment of the inflammatory process in patients with SARS, or others as they arise.
Inclusion Criteria:
- Patients of any age and gender, including minors and pregnant women.
- Hospital admission with diagnosis of COVID-19 according to clinical and
microbiological criteria established by the Health Authorities and clinical practice
(these may be modified based on the "Technical Document. Clinical management of
COVID-19: hospital care" of the Ministry of Health).
- Patients receiving any specific treatment for COVID-19 disease (according to the
"Technical Document. Clinical management of COVID-19: medical treatment" of the
Ministry of Health, and "Available treatments for the management of respiratory
infection by SARS-CoV-2" of the AEMPS).
- Patients admitted but not receiving specific treatment for COVID-19 disease
Exclusion Criteria:
- Patients who do not wish to give informed consent once requested.
Hospital Universitario Marqués de Valdecilla
Santander, Cantabria, Spain
Investigator: MAR GARCIA
MARIA DEL MAR GARCIA SAIZ, MDPhD
942203333
mmar.garcia@scsalud.es
LUCIA LAVIN ALCONERO, Phd
942203373
eclinicos5@idival.org